Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Nectin-2


Brief Information

Name:Transmembrane protein PVRIG
Target Synonym:PVRIG,PVR Related Immunoglobulin Domain Containing,CD112 Receptor,Poliovirus Receptor-Related Immunoglobulin Domain-Containing Protein,Poliovirus Receptor Related Immunoglobulin Domain Containing,Nectin-2 Receptor,C7orf15,CD112R,Transmembrane Protein PVRIG,MGC2463
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

 Nectin-2 BLI

Loaded Human Nectin-2, Mouse IgG2a Fc Tag (Cat. No. CD2-H5257) on Protein A Biosensor, can bind Human PVRIG, His Tag (Cat. No. PVG-H52H4) with an affinity constant of 1.33 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

 Nectin-2 BLI

Loaded Human Nectin-2, Fc Tag (Cat. No. PV2-H5253) on Protein A Biosensor, can bind Human PVRIG, His Tag (Cat. No. PVG-H52H4) with an affinity constant of 0.456 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name



Poliovirus receptor-related 2 (PVRL2) is also known as nectin-2 and CD112 (formerly herpesvirus entry mediator B, HVEB),  which is a human plasma membrane glycoprotein. PVRL2 is one of the plasma membrane components of adherens junctions. PVRL2 also serves as an entry for certain mutant strains of herpes simplex virus and pseudorabies virus, and it is involved in cell to cell spreading of these viruses. Variations in PVRL2 gene have been associated with differences in the severity of multiple sclerosis. Also, PVRL2 binds with low affinity to TIGIT. Furthermore, PVRL2 acts as a receptor for herpes simplex virus 1 (HHV-1) mutant Rid1, herpes simplex virus 1 (HHV-2) and pseudorabies virus (PRV).

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
COM-701 COM-701 Phase 2 Clinical Compugen Ltd Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lung Neoplasms Details
SIM-0348 SIM-0348 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Neoplasms Details
GSK-4381562 SRF-813; GSK-4381562 Phase 1 Clinical Surface Oncology Inc Neoplasms Details
NM1F NM1F; TGI-2 Phase 1 Clinical Hefei TG ImmunoPharma Co Ltd Solid tumours; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Melanoma Details
SHR-2002 SHR-2002 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Neoplasms Details
JS-009 JS009; TAB009; JS-009 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms Details
PM-1009 PM1009 Phase 1 Clinical Biotheus Inc Solid tumours; Neoplasms; Lung Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message